Does Medicare Cover Zepbound for Sleep Apnea? Coverage Rules After the 2024 FDA Expansion

Key Takeaways

• Yes, Medicare Part D plans can now cover Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (BMI 30+), following the December 2024 FDA approval of this indication.
• Coverage requires documented obstructive sleep apnea diagnosis (typically via sleep study with AHI of 15+) and BMI of 30 or higher.
• Medicare does not cover Zepbound for weight loss alone. The sleep apnea indication is the path to coverage for many Medicare patients with obesity.
• Typical Medicare Part D out-of-pocket cost ranges from $50 to $500 per month, depending on plan design and deductible status. Manufacturer savings cards don't apply to Medicare patients.
• Prior authorization is universal for Medicare Part D Zepbound coverage. Documentation of OSA via sleep study is the most important supporting record.

Direct answer (40-60 words)

Yes, Medicare Part D plans can cover Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity following the December 2024 FDA-approved expanded indication. Coverage requires documented OSA, BMI of 30+, and prior authorization. Medicare does not cover Zepbound for weight loss alone. Typical copays run $50 to $500 monthly.

Table of contents

1. The 30-second answer
2. The 2024 FDA expansion and what it changed
3. The SURMOUNT-OSA trial: what the evidence showed
4. Medicare Part D coverage criteria for Zepbound for OSA
5. How to qualify and document
6. Cost: what Medicare patients actually pay
7. The savings card exclusion for Medicare
8. Step-by-step: getting coverage approved
9. What if your Part D plan denies
10. FAQ
11. Sources
12. Footer disclaimers

The 2024 FDA expansion and what it changed

In December 2024, the FDA approved an expanded indication for Zepbound: treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first FDA-approved drug treatment for OSA in adults.

Before this approval, OSA was treated almost exclusively with continuous positive airway pressure (CPAP) therapy, oral appliances, or surgery. None of those treatments addresses the underlying obesity that drives most adult OSA cases. Tirzepatide, by producing weight loss, addresses the cause rather than just managing the symptom.

What this expansion changed for Medicare patients:

• Before December 2024: Medicare covered Zepbound for nothing. Federal law (the Medicare Modernization Act of 2003) prohibits Medicare Part D from covering drugs used for weight management.
• After December 2024: Medicare can cover Zepbound for OSA, since OSA is a covered medical indication, even though weight loss is the mechanism.

This is a meaningful coverage path for Medicare patients with obesity who also have diagnosed OSA, which is a substantial population. The American Academy of Sleep Medicine estimates that 25 to 30% of US adults have OSA, with prevalence rising sharply with BMI.

The SURMOUNT-OSA trial: what the evidence showed

The FDA approval was based on the SURMOUNT-OSA trial (Malhotra et al., NEJM 2024), a 52-week randomized controlled trial of tirzepatide in adults with moderate-to-severe OSA and obesity.

Key findings:

Outcome	Tirzepatide 15 mg	Placebo
Reduction in apnea-hypopnea index (AHI)	25 events/hour	5 events/hour
% achieving AHI under 15 (mild OSA)	50%	17%
Average weight loss	18.1%	1.3%
% no longer requiring CPAP	43%	14%

Patients who received tirzepatide 15 mg had a 5-fold greater reduction in apnea events than placebo. About half achieved an AHI low enough to be reclassified as mild OSA, and 43% no longer needed CPAP at study end.

The clinical takeaway: tirzepatide isn't a CPAP replacement for everyone, but it produces meaningful improvement in OSA severity for a substantial fraction of patients. For some, it eliminates the need for CPAP. For others, it allows lower CPAP pressures or makes therapy more tolerable.

Medicare Part D coverage criteria for Zepbound for OSA

Each Medicare Part D plan sets its own formulary, but most major plans (Aetna, Humana, UnitedHealthcare, BCBS plans, Cigna) added Zepbound for OSA in early 2025 following the FDA expansion.

Typical Part D coverage criteria:

• Documented diagnosis of moderate-to-severe obstructive sleep apnea (AHI of 15 events per hour or higher)
• Sleep study report from polysomnography or home sleep apnea test within the past 24 months
• BMI of 30 or higher at time of prescription
• Failure or intolerance of CPAP therapy, or documented OSA persisting despite CPAP use
• No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Prior authorization required, typically 6 to 12 month initial approval

Key documentation needed for PA:

• Sleep study report (polysomnogram or home sleep test)
• BMI calculation in chart
• Documentation of CPAP trial or intolerance (some plans require this; others don't)
• Provider attestation of clinical necessity

The CPAP trial requirement varies by plan. Some plans require a documented CPAP attempt before approving Zepbound. Others accept Zepbound as first-line for OSA in obese patients. Check your specific plan's PA criteria.

How to qualify and document

If you're a Medicare patient with obesity and you suspect you have OSA, the path to Zepbound coverage looks like:

Step 1: Get a sleep study. If you haven't had one, request a sleep study through your primary care physician. Medicare covers sleep studies (polysomnogram or home sleep apnea test) when there's clinical suspicion of OSA. Symptoms that justify a study: loud snoring, witnessed apnea episodes, daytime sleepiness, BMI over 30.

Step 2: Confirm the diagnosis. The sleep study generates an AHI score. AHI of 5 to 14 is mild OSA. AHI of 15 to 29 is moderate. AHI of 30+ is severe. Zepbound coverage requires moderate or severe OSA (AHI 15+).

Step 3: Try CPAP if your plan requires it. Some Part D plans require a documented CPAP trial before approving Zepbound. CPAP intolerance can include: inability to keep mask on, persistent skin irritation, claustrophobia, ongoing OSA symptoms despite use. Document the trial duration, settings, and reason for failure.

Step 4: BMI verification. Your BMI at the time of prescription must be 30 or higher. If you've started losing weight already, document baseline BMI from earlier records.

Step 5: Provider submits PA. Your provider submits the prior authorization with the sleep study, BMI, and other supporting documentation. Approval typically takes 3 to 14 days. If approved, the prescription is filled at your tiered Part D copay.

Cost: what Medicare patients actually pay

Medicare Part D Zepbound cost varies by plan and stage of the year. The typical 2026 Part D structure:

Coverage stage	Patient cost range	Notes
Annual deductible (up to $590)	Full cost up to deductible	Often $1,000+ first fill
Initial coverage	$40 to $300/month	Tier-based copay
Coverage gap (donut hole)	25% of plan's cost	Approximately $250 to $500/month
Catastrophic	$0 (Medicare pays 100%)	After total OOP exceeds threshold

The 2025 Inflation Reduction Act change: Starting in 2025, Medicare Part D capped annual out-of-pocket prescription costs at $2,000. Once a Medicare patient hits $2,000 in OOP costs, the rest of the year is free. For Zepbound at typical Part D copays, patients hit the cap by month 4 to 6 of the year, then pay nothing until January.

Realistic 2026 annual cost for a Medicare patient on Zepbound:

• January (deductible phase): $1,000 to $1,200
• February to May (initial coverage): $40 to $300/month
• After $2,000 OOP cap: $0 for the rest of the year

Total annual: roughly $2,000 (the cap), regardless of plan.

This is meaningfully more affordable than 2024, when Medicare patients paying out of pocket could spend $10,000+ per year on these medications.

The savings card exclusion for Medicare

The Lilly Zepbound savings card, which can reduce commercial insurance copays to $25 per month, is not available to Medicare patients. Federal anti-kickback laws prohibit manufacturers from offering copay assistance to government-program beneficiaries (Medicare, Medicaid, TRICARE, VA).

Medicare patients also cannot use:

• The Lilly Zepbound savings card
• Most manufacturer copay assistance programs (with exceptions for income-based patient assistance)
• GoodRx coupons combined with Medicare (you can use one or the other, not both)

What is available to Medicare patients:

• Standard Part D coverage with PA
• The $2,000 annual OOP cap (helps but doesn't reduce monthly costs in early year)
• Patient assistance programs through LillyCares for low-income patients (income below 400% of federal poverty level)
• Lilly Direct vials at $349 to $549 per month (cash payment, useful in coverage gap)

For most Medicare patients, the realistic monthly cost on Zepbound is $40 to $300 during the initial coverage phase, with the annual total capped at $2,000.

Step-by-step: getting coverage approved

The full sequence from "I think I should try Zepbound for OSA" to "first prescription filled":

Step 1: Schedule a primary care appointment. Discuss OSA symptoms (snoring, daytime sleepiness, witnessed apneas, fatigue). Request a sleep study referral.

Step 2: Complete the sleep study. Polysomnogram in a sleep lab or home sleep apnea test. The AHI from this study determines OSA severity.

Step 3: Review results with provider. If AHI is 15 or higher, you have moderate-to-severe OSA and meet that PA criterion. Your provider documents the diagnosis.

Step 4: Calculate BMI. Provider documents BMI at the visit. If 30 or higher, you meet the obesity criterion.

Step 5: CPAP trial (if plan requires). Some plans require a 30 to 90 day documented CPAP trial before approving Zepbound. Discuss with provider whether this is needed for your specific plan. CPAP intolerance must be documented if you can't tolerate it.

Step 6: Provider submits PA. Your provider submits the prior authorization to your Part D plan via electronic prior authorization or fax. Documents needed: sleep study report, BMI, prescriber notes, CPAP trial documentation if applicable.

Step 7: Wait for approval. PA decisions are typically returned within 3 to 14 days. Urgent PAs (when delay would harm health) can be expedited to 72 hours.

Step 8: Fill the prescription. Once approved, take the prescription to your Part D-participating pharmacy. The pharmacy processes the claim through your Part D plan and you pay your tiered copay.

Step 9: Schedule follow-up sleep study (12 months). Most plans require a follow-up sleep study at 12 months to demonstrate continued benefit and justify ongoing coverage.

What if your Part D plan denies

Denials happen, especially in the first months after a new indication is added. The appeal pathway:

Level 1: Redetermination. Submit a written request within 60 days. Include all clinical documentation. Plan responds within 7 days for standard requests, 72 hours for expedited.

Level 2: Reconsideration by independent review entity (IRE). If Level 1 is denied, escalate to an IRE. The IRE is a contractor independent of the Part D plan. Decision typically within 7 to 14 days.

Level 3: Administrative law judge. For amounts in dispute exceeding $190 (2026), an ALJ hearing is the next step.

Level 4: Medicare Appeals Council. For continued disputes after ALJ.

Level 5: Federal court.

In practice, most successful appeals happen at Level 1 or Level 2. The most common reasons for initial denial: incomplete sleep study documentation, BMI not in chart, PA submitted without all required forms. Provider-supported appeals with comprehensive documentation succeed at meaningfully higher rates than patient-only appeals.

If your plan continues to deny coverage despite appeals, your alternatives include Lilly Direct ($349 to $549/month for vials), compounded tirzepatide via telehealth ($279 to $499/month), or switching to a different Part D plan during the annual enrollment period (October 15 to December 7).

FAQ

Does Medicare cover Zepbound for sleep apnea? Yes, since the December 2024 FDA approval of the OSA indication. Medicare Part D plans can cover Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Prior authorization is required.

Does Medicare cover Zepbound for weight loss? No. Federal law (the Medicare Modernization Act) prohibits Medicare Part D from covering drugs used solely for weight management. The OSA indication is a covered medical use, even though the mechanism involves weight loss.

What's the BMI requirement for Medicare Zepbound coverage for OSA? BMI of 30 or higher at the time of prescription. This is the obesity threshold and matches the FDA-approved indication for Zepbound for OSA.

What's the AHI requirement for Medicare Zepbound coverage? Apnea-Hypopnea Index of 15 events per hour or higher (moderate-to-severe OSA). AHI is determined by polysomnography or home sleep apnea test.

Do I have to fail CPAP first to get Zepbound? Some Medicare Part D plans require documented CPAP trial or intolerance before approving Zepbound. Other plans approve Zepbound as first-line for OSA in obese patients. Check your specific plan's PA criteria.

How much will I pay for Zepbound on Medicare? Typical 2026 Medicare Part D copays run $40 to $300 per month during initial coverage, after a deductible of up to $590. Once your annual OOP costs reach $2,000 (the IRA cap), you pay nothing for the rest of the year.

Can I use the Lilly Zepbound savings card if I'm on Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare patients. The savings card is only available to commercial insurance members.

Does Medicare Advantage cover Zepbound for OSA? Yes, when the underlying Part D component is structured to cover Zepbound for OSA. Most major Medicare Advantage carriers added Zepbound for OSA to their formularies in early 2025. Specific tier and copay vary by plan.

Will my Medicare Part D plan cover Zepbound for both OSA and weight loss? The covered indication is OSA. The drug also produces weight loss as a side effect, but Medicare's coverage isn't for weight loss; it's for OSA. The distinction matters for documentation: your PA must reference OSA, not weight management.

What if I had a sleep study years ago? Does that count? Most plans require a sleep study within the past 24 months. If your sleep study is older than that, you'll likely need a new one to demonstrate current OSA severity. Talk with your provider about scheduling a repeat study.

Can a home sleep apnea test (HSAT) be used instead of an in-lab study? Yes, in most cases. Medicare covers home sleep apnea tests for patients with high pre-test probability of OSA. The AHI from a HSAT is generally accepted for PA documentation, though some plans prefer in-lab polysomnography for severe OSA cases.

Will I still need CPAP after starting Zepbound? Possibly not, depending on your weight loss response. The SURMOUNT-OSA trial showed 43% of tirzepatide patients no longer needed CPAP at 52 weeks. The other 57% still needed CPAP, often at lower pressures than before. Don't stop CPAP without provider guidance.

What happens at my 12-month renewal review? Most plans require a follow-up sleep study at 12 months and documentation of continued OSA or weight loss to renew Zepbound coverage. If OSA has resolved (AHI under 5) and weight is stable, some plans may not renew, since the coverage is for OSA. Discuss with your provider before the renewal.

Sources

1. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
2. Eli Lilly. Zepbound (tirzepatide) prescribing information, 2024 expanded indication revision.
3. FDA. Zepbound approval for obstructive sleep apnea, December 2024 announcement.
4. Centers for Medicare & Medicaid Services. Medicare Part D coverage of weight-loss drugs and the OSA exception. CMS guidance, 2025.
5. American Academy of Sleep Medicine. Adult obstructive sleep apnea: epidemiology and treatment guidelines. AASM 2024.
6. Inflation Reduction Act. Public Law 117-169, Medicare Part D out-of-pocket cap provisions, effective 2025.
7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
8. Kaiser Family Foundation. Medicare Part D appeals: trends and outcomes. KFF 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Medicare is a federal program administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.